Medical cannabis company Leafwell today provided an update regarding its ongoing legal dispute with Florida-based competitor My Florida Green (MFG), including MFG’s voluntary dismissal of its own lawsuit.
In October 2025, MFG filed suit against Leafwell alleging deceptive practices and simultaneously pursued widespread media coverage of its claims. At the time, Leafwell declined public comment while the original case was pending.
Since then, the U.S. District Court for the Middle District of Florida issued a sanctions order addressing filings submitted by MFG’s in-house counsel in the federal proceeding initiated by MFG. The court found that certain filings contained inaccurate legal citations and references to authorities the court could not locate, noting that the issues were consistent with the use of generative artificial intelligence without adequate verification.
Following the Court’s order, MFG voluntarily dismissed its own original case against Leafwell.
Although the broader dispute remains ongoing, the court’s findings and sanctions order order raise significant concerns regarding the credibility of MFG’s claims.
“These findings reinforce what we have consistently maintained: Leafwell operates with the highest regard for patient care,” said Leafwell CEO Emily Fisher in a statement. “If competitors are dissatisfied with our success in Florida, they should compete on care, cost, and patient education. While My Florida Green invests in litigation as a mechanism of making gains in the marketplace, we remain focused on making medical cannabis more accessible and affordable for every Floridian who could benefit from it.”
MFG's lawsuit alleged that Leafwell engaged in unlawful inducements, including offering “free” certifications paid for by dispensaries; deceptive practices, including failing to disclose that dispensaries were footing the bill; and patient brokering schemes, including steering patients toward specific dispensaries.
